Evidence map›Paper›PMID 38684989›Full record

ArticleBMC pulmonary medicine2024

The diagnostic impact of fractional exhaled nitric oxide for asthmatic cough in nontuberculous mycobacterial pulmonary disease.

Mari Miki, Keisuke Miki, Eri Akiba, Hiroyuki Kagawa, Yohei Oshitani, Takanori Matsuki, Kazuyuki Tsujino, Seigo Kitada, Ryoji Maekura, Hiroshi Kida

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mari MikiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan. mmaryys@gmail.com.
Keisuke MikiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Eri AkibaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Hiroyuki KagawaSenri Rehabilitation Hospital, Osaka, Japan.
Yohei OshitaniKodama Hospital, Hyogo, Japan.
Takanori MatsukiDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Kazuyuki TsujinoDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Seigo KitadaKitada Respiratory Clinic, Osaka, Japan.
Ryoji MaekuraDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Hiroshi KidaDepartment of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan.
Toneyama National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMeasurement of exhaled nitric oxide (FeNO) is a potentially useful diagnostic test for asthma. However, no study has explored the relationship between FeNO and respiratory symptoms of nontuberculous mycobacterial pulmonary disease (NTM-PD) complicated with asthma. The objective of this study was to assess the utility of measuring FeNO levels in patients with NTM-PD complicated by asthma.

methodsIn this single-center retrospective cohort study, 140 NTM-PD patients with FeNO measured were enrolled. We selected NTM-PD patients who complicated with asthma as the NTM+BA group, defined using the following criteria: NTM patients with symptoms consistent with asthma, and NTM patients with symptomatic improvement after diagnostic therapy with ICS ± a long-acting beta 2-agonist (LABA). We then calculated a diagnostic cutoff point to distinguish between the NTM+BA groups and the NTM groups (all others). High-resolution computed tomography (HRCT) images were evaluated using the CT scoring system and their association with FeNO was examined.

resultsA total of 89 patients were included in the study. (31 in the NTM+BA group and 58 in the NTM group). Compared with the NTM group, the NTM+BA group had higher rates of allergic disease (51.6% vs. 22.4%; p=0.0085) and higher FeNO values (median, 23 [interquartile range {IQR}, 15.0-43.0] ppb vs. median, 17 [IQR, 11.8-23.0] ppb; p=0.015). With diagnostic asthma care using mainly ICS/LABA with reference to the FeNO, most patients (91.0%, 20/22) in the NTM-preceding subgroup in the NTM+BA group demonstrated a prompt improvement of their symptoms and AFB culture findings did not worsen (Culture positive rate (%): Pre-treatment: 59.1% vs. Post-treatment: 40.9%, p=0.3660) at 6 months after starting diagnostic therapy. The optimal diagnostic cutoff point of FeNO to distinguish between the two groups was calculated as 21.5 ppb by the ROC curve (sensitivity 75%, specificity 71.93%, p<0.0001; area under the curve: 0.7989). No significant correlation was observed between FeNO and the severity of CT images in the patients.

conclusionsA certain number of patients with NTM-PD showed exacerbated respiratory symptoms due to asthmatic complications. Elevated FeNO levels suggest asthma complications, even in patients with NTM.

Indexed as

AsthmaCoughMycobacterium Infections, NontuberculousNitric OxideAgedBreath TestsFemaleFractional Exhaled Nitric Oxide TestingHumansMaleMiddle AgedRetrospective StudiesROC CurveTomography, X-Ray ComputedNitric OxideAsthmaBronchial ectasiaExhaled nitric oxideHigh-resolution computed tomographyNontuberculous mycobacteria

Identifiers

PMID38684989
PMCPMC11059766
OpenAlexW4396219169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.